INTERPRETATION Most families found supplementation feasible. No statistically significant differences in neurodevelopmental outcome between the treatment and comparison groups were identified. Further investigation of neurodevelopmental outcome after supplementation with DHA, choline, and UMP of infants with suspected CP is warranted.
The developing brain may have some capacity to alter its structure and function in response to injury through processes of plasticity. There may be 'critical periods' or temporal windows in brain development during which there is increased potential for plasticity associated with maximal neural sensitivity to specific stimuli. These are periods of rapid neural maturation and extensive neural connectivity. Adequate macro-and micronutrient intake are essential for healthy brain development and can be manipulated in an attempt to support optimal neurodevelopmental outcome in at-risk groups. 1, 2 The structure and function of the central nervous system relies on a specific profile of phospholipids and their fatty acids. Phosphatidylcholine is the most abundant brain phospholipid, and comprises choline (an amine), uridine-5-monophosphate (UMP), a pyrimidine, and the long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA). 3 This process is rate-limited by the nutritional availability of DHA, UMP, and choline. DHA is also necessary for neurogenesis, neurite outgrowth, synaptic plasticity, axonal elimination, and gene expression. [4] [5] [6] [7] [8] Choline is a source of methyl groups (necessary for methylation of DNA and ribonucleic acid), a component of phosphatidylcholine and sphingomyelin, and is necessary for the production of the neurotransmitter acetylcholine. 9 UMP is important for synapse membrane production. 10 As adequate macro-and micronutrient intake is needed to support brain development, nutritional inadequacy may limit the brain's capacity for remodelling and repair after injury. 11 Rodent supplementation with a combination of DHA, choline, and UMP increases brain phosphatide levels, synaptic components, functional brain connectivity, and cognitive performance.
Brain injury occurring in the first 2 years of life, during maximal brain growth and development, may result in cerebral palsy (CP); 'a group of permanent disorders of movement and posture, causing activity limitation, which are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of CP are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems'. 13 CP remains a major cause of childhood disability worldwide, with a prevalence of 2 per 1000 live births.
14 Feeding difficulties such as oromotor impairment, dysphagia, and foregut dysmotility are common in children with CP 11 and may result in prolonged feeding times, reduced macro-and micronutrient intake, and growth failure without adequate nutritional support. Gastrostomy placement may be necessary to support optimal nutrition and growth for children with CP. 15, 16 Many feeding and nutritional interventions for children with CP are introduced once growth failure is already established, but they lack high-quality evidence of benefit. 17, 18 Novel early nutritional interventions aimed at reducing the level of disability experienced by children with CP are needed. 19 This study investigated whether nutritional intervention with DHA, choline, and uridine supplementation at maximal permissible levels improved neurodevelopmental outcomes in infants with suspected CP.
METHOD
We conducted a double-blind randomized placebo-controlled trial of DHA, choline, and uridine in infants with suspected CP. The trial protocol provides the full methodology. 20 
Participants
Consultant paediatricians from five collaborating multidisciplinary child development teams in the UK (Oxford, Reading, Slough, Milton Keynes, and High Wycombe/ Aylesbury) identified eligible infants. Inclusion criteria were children aged 1 to 18 months with suspected CP. Exclusion criteria were children with (1) progressive neurological conditions, or investigational evidence of non-CP neurological conditions which may initially mimic CP, (2) hearing impairments, unable to complete trial assessments, (3) gastrointestinal disease impairing absorption, (4) parents considered unable to follow the study protocol by clinicians, or (5) participants of a contemporaneous parallel randomized controlled trial assessing the neurodevelopmental outcomes of neonates with risk factors for neurodevelopmental impairments after dietary supplementation. 20 Paediatricians at participating child development centres identified families interested in receiving additional trial information to the research team. The research nurse sent the trial parent information sheet to interested families and arranged follow-up to answer any parental/carer questions after 5 to 7 days. Informed written consent was obtained from participating families during a home visit then followed by trial baseline assessments. Study ethical approval was granted by the Oxfordshire Research Ethics Committee B.
Participants were randomized by the University of Oxford's Centre for Statistics in Medicine, by minimization, stratifying by sex, age at randomization (1-5mo, 6-12mo, and 13-18mo), and pattern of motor involvement (four limbs or other) and visual impairment (yes/no). The trial principal investigators and team conducting neurodevelopmental assessments were blind to group allocation. The trial dietitian and research administrator were not blind to group allocation, but did not discuss children's treatment with other team members or parents. All information about group allocation and dietary information was held separately to the case report form, and accessed only by the research administrator or dietitian. The trial dietitian delivered product to the families.
Participants received daily treatment or control supplementation for 2 years. The study supplements were produced and quality control checked by Nutricia Advanced Medical Nutrition, Utrecht, the Netherlands. The active supplement contained the omega-3 fatty acids DHA (1% of total daily estimated fatty-acid intake) and eicosapentaenoic acid, the omega-6 fatty acid arachidonic acid, choline, UMP, cytosine monophosphate, vitamin B 12 , zinc, and iodine (nutrients that are also important to brain development) 21 (Table I) . Treatment and control supplement were produced on a background of infant formula and therefore contained a small amount of choline, vitamins, minerals, and trace elements.
The supplement products were processed to be similar in odour and/or taste and supplied in identical foil packages marked X and Y. Infants received 2g/kg/day (maximum 24g/ day), supplied as a combination of 2g, 3g, and 12g sachets, for 2 years, or while compliant with the study protocol. The What this paper adds
• This was the first trial of phosphatidylcholine precursor supplementation in infants with suspected cerebral palsy (CP).
• Families of infants with suspected CP found 2-year nutritional supplementation feasible.
• There was no statistically significant neurodevelopmental advantage for the treatment group versus the comparison group.
• However, treatment group cognitive and language advantage were of clinically meaningful magnitude.
supplement was mixed with usual formula or expressed breast milk and with wet foods on weaning, or delivered through a feeding tube. The trial dietician telephoned each family every 2 weeks initially, then as required, and made 3-monthly assessment visits to optimize dietary macro-and micronutritional intake, supplement tolerance, adherence, and growth, and to provide supplement. Study assessments and their timing are described in the trial protocol. 20 The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) were administered to children at baseline, 12 months, and 24 months in the child's home by one of two trained assessors (MJA or CM-J). The Vineland Adaptive Behavior Scales, Second Edition was administered to the parent (MJA or CM-J) after Bayley assessment. Neurophysiological and functional behavioural visual measures were performed at baseline, 12 months, and 24 months. Occipito-frontal circumference was measured using a Lasso-o tape measure at baseline and every 3 months. A mean from three measurements of the occipito-frontal circumference was calculated. One confidently obtained measurement was accepted in infants not compliant with measurement. Height, weight, and triceps skinfold thickness were also measured every 3 months. 20 Home dietary assessment occurred every 3 months. Dietary history using food recall over the previous week was recorded and used to advise families on optimal macro-and micronutrient intake. Dietary data were analysed using Dietplan 6 (Forestfield Software Ltd, UK).
Whole-blood fatty-acid samples were collected from participants by heel prick onto a Guthrie card at baseline and 24 months, and analysed using the method of Marangoni et al. 22 The primary outcome was the cognitive composite score of the Bayley Scales of Infant and Toddler Development, Third Edition (CCS-Bayley-III) at 24 months of supplementation. The Bayley-III is a standardized measure of neurodevelopment suitable for children aged 1 to 42 months with cognitive, language, and motor domains. 23 The Bayley-III composite score has a range of 40 to 160 and is a normalized transformation of a distribution of scores derived from normative tables of standardized scaled scores, composite scores, and centile ranks provided in the Bayley-III manual.
Reported secondary outcomes included the CCS-Bayley-III scores at 12 months, and language composite score of the Bayley Scales of Infant and Toddler Development, Third Edition (LCS-Bayley-III) and motor composite score of the Bayley Scales of Infant and Toddler Development, Third Edition (MCS-Bayley-III) at 12 months and 24 months. Parent-reported adaptive behaviour scores were measured by the Vineland Adaptive Behavior Scales, Second Edition, a standardized parent questionnaire assessing adaptive behaviour from birth to 90 years. 24 The measure provides a standard adaptive composite score standardized and normed for age (mean 100, [SD 15]), derived from standardized domain scores: communication, socialization, and daily living skills.
Statistical analysis
Statistical analysis was conducted according to the trial statistical analysis plan using STATA 14.1 (StataCorp, College Station, TX, USA, 2015). Sample size was calculated for 80% power to detect a 12.5-point difference in CCS-Bayley-III, at the 5% level for a two-tailed test. In total, a sample size of 48 participants were required, assuming an SD of 15. Assuming a 20% loss to followup, the recruitment target was increased to a total of 60 children.
Bayley-III scores at 12 months and 24 months of supplementation were analysed using mixed-effects linear regression to account for repeated measures at 12 months and 24 months. The model covariates were baseline Bayley-III score, time point (12mo/24mo), treatment group, an interaction between time point and treatment group, and the minimization factors of predominant pattern of motor development (four limbs or other), age at recruitment (1-5mo, 6-12mo, and 13-18mo), sex, and visual impairment (yes or no).
For primary outcome analysis, mean differences in CCSBayley-III between intervention groups at 24 months of supplementation are presented along with 95% confidence intervals (CI) and associated two-sided p-values, and the p-value for overall effect of treatment. No adjustment of p-values to account for multiple endpoints was made. Analyses of secondary Bayley-III and Vineland Adaptive Behavior Scales, Second Edition outcomes follow the procedure described for the primary outcome analysis.
Anthropometric measurements were converted to zscores before analysis. The z-scores were calculated using the World Health Organization Child Growth Standards STATA igrowup package (WHO Multicentre Growth Reference Study Group, 2007; http://www.who.int/child growth/software/readme_sas.pdf).
Mixed-effects regression models were fitted to the data, and the fitted difference in means between treatment and comparison groups at 12 months and 24 months presented alongside 95% CI and the associated two-sided p-values for the overall effect of treatment.
An independent trial data monitoring committee consisting of two senior consultant paediatric neurologists, an independent medical statistician, and the trial statistician reviewed safety and 12-month outcome data and recommended trial continuation.
The trial was registered with the International Standard Randomised Controlled Trial Number registry, number 15239951.
RESULTS

Recruitment was between 1 September 2009 and 28
December 2012. One hundred and ten infants were assessed for eligibility; 63 met eligibility criteria, 40 gave consent and were randomized (28 males, 12 females). Participant flow is summarized in the Consolidated Standards of Reporting Trials flow chart (Fig. 1) .
At baseline, median gestational age at birth was 3 weeks lower in the treatment group than the comparison group. Mean baseline CCS-Bayley-III score was 2.8 points higher in the comparison group than in the treatment group. Mean baseline LCS-Bayley-III score was 2.9 points higher in the treatment group than in the comparison group (Table II) .
Children who discontinued supplementation early and did not participate in subsequent study assessments were considered withdrawals. By 12 months, six treatment group children and one comparison group child had withdrawn (three out of six treatment group children and the comparison group child withdrew before supplementation started). A further comparison group child received minimal supplementation for 2 months before being lost to follow-up, leaving 14 treatment group and 18 comparison group children respectively. By 24 months, three further children (one treatment group and two comparison group) had withdrawn, leaving 13 treatment group and 16 comparison group children.
Duration of supplementation varied between participants. Six treatment group and 10 comparison group children completed 2 years of supplementation. A further seven treatment and six comparison group children completed between 1 year and 2 years' supplementation. Two treatment group children and one comparison group child completed more than 8 weeks but less than 1 year of supplementation, and eight children completed less than 8 weeks' supplementation (five in the treatment group and three in the comparison group).
Two protocol violations occurred. One infant withdrew before supplementation but contributed neurodevelopmental data to the comparison group at 12 months. One infant was randomized to receive control supplement but received treatment supplement for 2 years. This child was analysed in the comparison group in the intention to treat analysis, which included 14 treatment group and 18 comparison group infants (Fig. 1) .
Treatment and comparison group baseline blood longchain polyunsaturated fatty-acid levels were similar. Mean blood DHA and eicosapentaenoic acid levels were higher in the treatment group at 24 months than the comparison group (p=0.07 and p=0.02 respectively).
Baseline CCS-Bayley-III data were available for 40 participants. Participants included in the intention to treat analysis had CCS-Bayley-III data at baseline and at least one other time point (n=32 (Fig. 2) . Analysis of LCS-Bayley-III data without minimization factors produced a mean modelled difference of 2.9 (95% CI À7.4 to 13. Difference in mean scores between treatment and control groups Mean motor composite scores of the Bayley-III were similar at 12 months and 24 months for the treatment and comparison groups, both with and without inclusion of minimization factors in the analysis (Fig. 2) .
Mean Vineland Adaptive Behavior Scales, Second Edition domain standard scores were non-significantly lower in the treatment than the comparison group (mean difference À5. 4 (Fig. 2) . Analysis of Vineland Adaptive Behavior Scales, 2nd Edition domain standard scores without inclusion of minimization criteria showed little difference between groups at 12 months (mean modelled difference À0.4 [95% CI À8.3 to 7.5]). At 24 months, the mean modelled difference was 2.2 (95% CI À5.7 to 10.2). There was no overall effect of treatment (v There were no between-group differences in occipitofrontal circumference at baseline and 24 months (modelled difference in mean z-score at 24 months À0.31 [95% CI À0.87 to 0.26], p=0.42). Height was greater in the comparison group than the treatment group; the fitted differences in means were À0.57 (95% CI À1.03 to À0.11) and À0.57 (95% CI À1.10 to À0.04) for 12 and 24 months respectively (p=0.02). There was no between-group difference in weight or triceps skinfold thickness at 12 months or 24 months (data not shown).
Overall, secondary outcome visual measures showed no differences between the treatment and comparison groups. Trial vision data will be reported separately (data not shown).
DISCUSSION
This is the first trial to explore the neurodevelopmental effect of provision of all three phosphatide precursors (DHA, choline, and UMP) at maximum permissible levels to infants with suspected CP. The trial showed a non-significant difference between infants in the treatment group and those in the comparison group for cognitive and language performance: CCS-Bayley-III scores were 4.4 points higher in the treatment group than in the comparison group and LCS-Bayley-III scores were 5.5 points higher in the treatment group. Despite not reaching statistical significance, we consider the between-group differences in Bayley-III cognitive and language scores of 4 to 5 points to represent clinically meaningful effects. 25 Recent nutritional intervention trials with Bayley-III as their primary outcome measure used point differences of 4 to 6 points to generate their sample sizes, identifying such an effect size to be clinically meaningful.
Although several trials have assessed the neurodevelopmental effect of DHA supplementation alone, no trial has previously provided all three phosphatidylcholine precursors in infancy. Furthermore, infant supplementation trials so far have been in typically developing infants and have not considered the effects of DHA supplementation of infants with suspected CP. 26 For all infants, supplementation began within the first 18 months of life, during the period of maximal brain growth and development, with the aim of supporting brain injury repair mechanisms after perinatal brain injury.
The treatment effects are not the result of a difference in macronutrient intake between the intervention groups (as this was optimized for both groups through dietitian support), or increased head circumference (brain size) among treatment group children, as this was similar at baseline and 24 months for both groups. There is some indication that, at 24 months after intervention, height was greater in the comparison group children. The causality of this finding is unclear and requires verification in a future trial. Neurodevelopmental findings are similar to those of a trial conducted in neonates with risk factors for neurological impairment (the Dolphin neonatal trial), which also demonstrated treatment group advantage in CCS-Bayley-III and LCS-Bayley-III performance. Although the findings were not statistically significant, between-group differences were of a magnitude that could be clinically meaningful if replicated in an adequately powered trial (MJ Andrew et al., unpublished material).
This novel trial recruited infants from UK National Health Service child development teams; thus children referred to the trial with suspected CP had been assessed by experienced multidisciplinary clinicians. Supplementation aimed to achieve DHA levels comparable to the maximal levels found in human breast milk (around 1% of total daily estimated fatty-acid intake) to optimize substrate availability to the developing brain. The high DHA dose, provided in combination with phosphatidylcholine precursors, choline, and UMP, through maximal brain growth and development was a major trial design strength. Compliance with supplementation was reasonable; of those who started supplement, most completed at least 1 year of supplementation (83%). Almost half of those who started supplementation completed 2 years' supplementation (46%). Supplementation led to higher mean DHA levels in the treatment group compared with the comparison group, indicating treatment fidelity was reasonable. Outcome measurements were completed by one of two trained assessors.
There are several limitations to the interpretation of the observed treatment group effects on Bayley cognitive and language performance. Clinical challenges surrounding the early identification of infants with CP contributed to recruitment of fewer infants than required. 27 This was exacerbated by running the Dolphin neonatal trial in the same geographical area, meaning some children with suspected CP had started supplementation as neonates and were therefore excluded from this trial. Combined with a higher than expected withdrawal rate, these factors resulted in the trial being underpowered. A much larger sample size would be necessary in any future trial that aims to replicate the findings of the current trial. A higher withdrawal rate in the treatment group than the comparison group may indicate some alteration of taste or texture of food after supplementation, despite similar processing of the treatment and control products. The small numbers in each group necessitate cautious interpretation. Stratification allowed reasonable comparison between groups; however, chance differences in predominant patterns of motor involvement, aetiology, comorbidity, age at recruitment, variation in the home environment, and developmental stimulation between participants during the time course of the study may have resulted from the small sample size.
It is possible that the primary outcome measure used was insufficiently refined to identify a statistically significant treatment effect even though one existed. As childhood progresses, it is possible to make finer neurodevelopmental assessments using a range of robust assessment tools. Studies assessing the neurodevelopmental outcomes of the Dolphin infant cohort at preschool and school ages are currently being conducted, to establish any long-term effects of early nutritional supplementation that might only become identifiable as cognitive demands increase with age. While acknowledging the limitations of this study, if a treatment effect was shown in an adequately powered future study, children with CP may stand to benefit from nutritional supplementation in early childhood. Such findings would have important implications for the nutritional management of children with CP, and advance our understanding of the role of nutrition in brain development after perinatal brain injury. Furthermore, clinically significant functional improvements in cognitive and language ability would have important implications for education and social participation. on the visual aspects of the study and consultants to the project as a whole. The Dolphin infant nutritional intervention trial was supported by grants from SPARKS, the Oxford Biomedical Research Centre, and the Thames Valley Clinical Research Network. The University of Oxford acted as trial sponsor. The supplements were developed and supplied at no cost by Nutricia Ltd, based in the Netherlands. Nutricia had no role in the development of the protocol, the planning or running of the trial, or the analysis of data. Nutricia provided information about the supplement but did not otherwise contribute to the content of the manuscript. PBS has received lecture fees from Nutricia Ltd and is a member of the Advanced Medical Nutrition Scientific Advisory Board. MJA has received Nutricia sponsorship to attend scientific meetings. The other authors have stated that they had no interests which might be perceived as posing a conflict or bias.
